Cellectis SA Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
Bpifrance and Caisse des Depots group's beneficial ownership percentage in Cellectis S.A. decreased due to an increase in the issuer's outstanding shares and voting rights, not through direct transactions.
NASDAQ
An amended Schedule 13D filing by several French state-backed entities clarifies their beneficial ownership and voting rights in Cellectis S.A., detailing differing percentage calculations under U.S. and French law.
NASDAQ
AstraZeneca and its subsidiary now hold a 44% stake in Cellectis after converting preferred shares, with the ability to resell these shares publicly.